BioSample Availability Request Form

If you are interested in requesting non-renewable samples from a specific collection or collections stored at the NIDDK Repository, you must apply for access via a Repository-specific funding announcement. Your X01 (PAR-14-301), R01 (PAR-13-228) application needs a summary of sample availability from us. To obtain the summary of sample availability, update and submit the form below and a member of the NIDDK Central Repository staff will contact you soon. If desired, you may save the form instead and return to complete it at a later time. If you would like to provide sample availability information for an application to a different funding opportunity, please fill out the form below and submit it. However, sample access can only be granted through a successful application to the Repository-specific funding announcements noted above.

* = Required Field

BioSample Availability Request

Request Name*

Investigation of Outcome A in the DCCT/EDIC Cohort

Create a nickname for your reference

Requestor Information

Name*

John Doe

Email*

john.doe@university.edu

Address*

123 Main Street
Anytown, US 12345

Title

Postdoctoral Fellow

Institution

University of Anytown

Phone

111-222-3333

Fax

111-222-4444

Website

www.university.edu/mylabpage/

A URL for the requestor if they have a site.

PI Name*

Dr. Jane N. Charge

PI Institution*

Any Place University

PI Email*

jane.charge@apuniversity.edu

Support Information

Support Type

NIH Extramural Funding Award Number

Other

PAR

PAR-11-306

Other

Grant/PAR Number

Request Details

Study*

(DCCT/EDIC) Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications

Select the desired studies. Hold down "Control", or "Command" on a Mac, to select more than one.

Desired Number of Specimens*

230-270

Approximate count of specimens required for your study.

Minimum volume (or mass if requesting DNA)*

80-120ul

Please include units.

Material Type(s)*

Serum

Specimen requirements*

Ideally, samples that have not been freeze-thawed or have only undergone a few freeze-thaw cycles.

Describe any additional requirements pertaining to the biospecimens themselves, such as anticoagulant used, additives, preservatives, etc.

Subject characteristics*

Subjects are described in Turkbey et al, "Myocardial Structure, Function, and Scar in Patients with Type 1 Diabetes Mellitus", Circulation 2011: 124: 1737-1746 (see attached)
Subgroup 1) n = 17 patients who died of Outcome A from years 14-16 of DCCT/EDIC Please see Fig X, of Turkbey et al.
Subgroup 2) n ~ 100-130. Patients with Outcome B excluded from Analyte 1 administration (n=262 total, in Fig. X) who had Outcome B or Outcome C. This number ("n ~ 100-130") is based on an estimate that 40-50% of T1D renal failure patients will had had Outcome B or Outcome C, based on the knowledge that Outcome A is disproportionately severe in this subgroup.
Subgroup 3) ClinicalMeasure1 by Technique1 (Table 4) n = 32
Subgroup 4) Outcome A n = 41 patients
Subgroup 5) DCCT/EDIC patients with ClinicalMeasure2 <50% (See Table 2; n=?)

Describe the characteristics of the subjects to be searched for available specimens. Criteria might include gender, age, disease status, genotype, etc. Be as specific as possible.

Information Security: Please check the information security practices to be used

- [x] Institute supported, controlled access server
- [x] Institute supported, password protected desktop computer
- [ ] Encrypted, password protected laptop computer
- [ ] Encrypted portable media (encrypted external hard drive, encrypted thumb drive)
- [ ] Unencrypted portable media backup (CD, DVD, thumb drive) stored in locked file cabinet

Study data must be maintained in a secure and controlled environment

Comments

I am interested in applying to the upcoming PAR, due Feb 5th 2014. This request does not include samples from control T1D subjects without complications matched for age, gender, and duration of diabetes. The controls are most relevant to the analysis of subgroups 3, 4 and 5.